FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria di Stack

AOD-9604 Frag Stack

Fat Lossbeginner

81

sintesi

81
Share
Peptidi

2

Media giornaliera mcg

600

Livello

beginner

Aggiunto

May 17, 2026

Panoramica

The AOD-9604 Frag Stack combines AOD-9604''s direct fat-burning action with Ipamorelin''s GH pulse support, creating a two-part protocol that attacks fat during the fasted morning window and optimizes GH output during nocturnal sleep — the two periods of highest natural fat metabolism. AOD-9604 (also known as Fragment 176-191) is a modified fragment of human growth hormone''s C-terminus that retains GH''s lipolytic (fat-breaking) activity without its growth-promoting, insulin-sensitizing, or IGF-1-raising effects. This makes it unusually clean: it specifically mobilizes stored fat for energy through fat cell receptor activation without the side effects associated with full GH or GH secretagogues. It was studied in human clinical trials by Metabolic Pharmaceuticals and showed statistically significant fat reduction with minimal adverse events. Ipamorelin is dosed before sleep to amplify the natural nocturnal GH pulse — the body''s primary growth hormone secretion window. This GH pulse drives fat metabolism during sleep and supports lean tissue preservation and growth. Because Ipamorelin is highly selective (no cortisol, no appetite stimulation), it is the cleanest GHRP choice to pair with a pure fat loss compound. The timing split is intentional: AOD-9604 in the morning fasted state capitalizes on the low-insulin environment for maximum lipolysis, while Ipamorelin at night amplifies the nocturnal GH pulse. Together they target fat loss across both the AM and PM metabolic windows.

Protocollo di Dosaggio

AOD-9604 (Fragment 176-191)

daily (fasted AM)· subcutaneous

Leggi di più su AOD-9604 (Fragment 176-191) →

300 mcg

per dose

Ipamorelin

daily (before bed)· subcutaneous

Leggi di più su Ipamorelin →

300 mcg

per dose

Obiettivi & Evidenze

Targeted fat lossLipolysisGH optimizationBody composition
Livello di Evidenza:Dati umani

Avvertenze

  • AOD-9604 is not FDA-approved for weight loss. Human clinical data exists but registration was not pursued.

Comments

Sign in to join the discussion

Avvertenza: Questo stack è compilato dalla comunità e a scopo di ricerca solo. Peptide Contacts non verifica la sicurezza o l'efficacia dei stack compilati. Consulta sempre un professionista sanitario qualificato prima di utilizzare qualsiasi protocollo di peptidi.